TauC3 Biologics is pioneering a precision immunotherapy approach aimed at addressing tau-related neurodegenerative diseases, specifically frontotemporal dementia (FTD-tau) and progressive supranuclear palsy (PSP). The company's lead candidate, TBL-100, is a humanized monoclonal antibody that specifically targets tauC3, a truncated and particularly harmful form of tau protein. This targeted approach is designed to slow or halt the progression of tau pathology, which is implicated in cognitive decline and neurodegeneration. Preclinical studies have shown promising evidence of TBL-100's engagement with its target, and the company is also developing diagnostic tools that leverage the specificity of TBL-100 to aid in patient selection and treatment monitoring.

The scientific foundation of TauC3 Biologics' work is rooted in understanding the mechanisms of tau pathology dissemination in the brain. Research indicates that tau pathology begins with the release of abnormal tau from neurons, particularly in the entorhinal cortex, leading to its internalization by connected neurons. TauC3, produced through caspase-3 cleavage of full-length tau, is identified as the most noxious form of tau, significantly contributing to the spread of tau pathology. The company posits that soluble oligomers of tauC3 play a critical role in this process, as they are more readily internalized by neurons compared to other tau species, thereby facilitating the progression of neurodegenerative conditions.

United Kingdom

A new approach to halting the spread of tau pathology and destruction of nerve cells in the brain

Precision immunotherapy for the treatment of tau-related frontotemporal dementia (FTD-tau) and progressive supranuclear palsy (PSP)

TauC3 Biologics

Company Details